New Drug Prior Authorization Removals Beginning July 1, 2018

Effective dates of services from July 1, 2018, and forward, UCare will NOT require a prior authorization on the following injectable drugs for members on our UCare Plans.

- **Botulinum Toxins** (Botox, Dysport, Myobloc, and Xeomin)
- **Immune Globulins** (Privigen, Gammagard, Carimune, Gamunex, Hizentra, Bivigam, Gammaplex, Vivaglobin, Octagam, Flebogamma, Glebogamma, HyQvia, Immune Globulin NOS)
- **Viscosupplementation Knee Injections** (Gel-One, Hylgan, Orthovisc, Supartz)
- **Remicade**

UCare requirements for a prior authorization on Prolia have also changed:

- **Prolia**: Prior Authorization will only be required for UCare Medicare plans (UCare For Seniors, EssentiaCare, Minnesota Senior Health Option and Connect + Medicare).

Each year, UCare conducts an annual review of the list of drugs requiring prior authorization. The Pharmacy and Therapeutics Committee releases the review in the fall before the year it takes effect, with additional reviews during the year, as needed. The full list of drugs requiring prior authorization are available at [UCare’s Pharmacy page](#).

*Although the drugs above will no longer require a Prior Authorization claims will be denied for excluded or investigational uses (for example cosmetic uses).*